Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EO2463 Monotherapy and Combination Therapy in Indolent Non-Hodgkin's Lymphoma
NCT04669171Phase 2Active, not recruiting
- Sponsor
- Enterome
- Start
- Jul 2021
- Primary completion
- May 2029
- Modality
- Antisense DNA, Prophylactic Vaccines, Small Interfering RNA (siRNA)
- Countries
- 4
01
Overview
Phase 2, open-label trial of EO2463 in follicular lymphoma (FL) and marginal zone lymphoma (MZL) (4 cohorts), sponsored by Enterome. Primary endpoints: Recommended Phase 2 Dose at 24 months, Adverse Events Assessment at 24 months and 2 more. Started Jul 2021; status: active, not recruiting.
02
Drugs
EO2463
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04669171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669171.